New market study, "China Pharmaceuticals & Healthcare Report Q2 2016", has been published

The merger of China's new rural cooperative medical scheme with its urban residents basic medical insurance scheme will reshape the country's healthcare landscape. This will have important ramifications for the pharmaceutical industry as reimbursement models shift correspondingly. While this perpetuates the shifting dynamics within China in 2016, the long-term impacts are positive - expanding the depth of coverage to more patients and improving the system's financial sustainability.

Headline Expenditure Projections

Pharmaceuticals: CNY687bn (USD107bn) in 2015 to CNY770bn (USD115bn) by 2016; +12% in local currency terms and +7.1% in USD terms.

Healthcare: CNY4,078bn (USD639bn) in 2015 to CNY4,628bn (USD693bn) in 2015; +13.5% in local currency and +9.6% in USD terms.

Full Report Details at
- http://www.fastmr.com/prod/1112358_china_pharmaceuticals.aspx?afid=301

Risk/Reward Index

In Q216, China is amongst the most attractive countries according to our Pharmaceutical Risk/Reward Index. The country scores 64.0 out of 100 and is ranked sixth amongst 19 other Asia Pacific countries. Key to China's strong score is its high market expenditure, high sector value growth and policy continuity. The only limiting factors come from the country's business transparency and limited legal diligence.

Latest Updates

In December 2015, the government announced that it intends to merge the country's public health insurance schemes for rural and urban residents.

The China Pharmaceuticals and Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's China Pharmaceuticals and Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the China pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for China, to test other views - a key input for successful budgeting and strategic business planning in the Chinese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Chinese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in China.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q2 2016
- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016